Frontier mental health research: psychedelics & drug studies

Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.

3 papers

Ayahuasca for Depression

Based on 15 papers

Research on ayahuasca for depression is promising but still early. Lab and animal work shows that the brew’s active ingredient, DMT, can change brain circuits and help nerve cells form new connections, which could explain fast mood improvements seen in small human trials. At the same time, the human evidence comes from a few small or early-stage clinical studies, and scientists say more rigorous, larger trials are needed. Researchers also emphasize that the drug experience and the therapy around it matter a lot. Many studies point out limits in the data: not enough people from diverse backgrounds were included, peripheral blood markers like BDNF don’t give a clear answer, and some related compounds have serious risks at high doses. Overall, ayahuasca shows potential, but important questions about safety, who it helps, and how long benefits last remain open.

Key findings

  • Ayahuasca is a plant brew that combines DMT with other plants that block the body from breaking DMT down, so it works when taken by mouth. 15082
  • DMT and ayahuasca interact with serotonin-related brain receptors and can promote brain plasticity — meaning they can help nerve cells grow new branches and make new connections in lab and animal studies. 15050 15082 15059
  • Small clinical studies and some phase II trials report quick antidepressant effects after one or a few doses of DMT-containing treatments or ayahuasca, which is encouraging for treatment-resistant depression but still preliminary. 15082 15060 15063 15091
  • Many researchers say the way a session is run — preparation, the therapy given around the drug, the music, and feeling safe — strongly affects whether people improve, so benefits are not just the drug alone. 15092 15063 15091
  • A large review found no clear change in blood levels of brain-derived neurotrophic factor (BDNF) after psychoplastogen drugs in humans, so measuring blood BDNF has not been a reliable sign of brain change after these treatments. 15129
  • Trials so far are small and early-stage, and study samples often lack diversity; because of that, we do not yet know how well the results apply to all people or how long the effects last. 15085 15082 15095 15063
  • Safety signals are mixed: some clinical reports say treatments were generally tolerated in controlled settings, but related compounds (like high doses of ibogaine) have shown serious cardiac and neurological risks in past studies, and animal work shows dose- and sex-dependent differences — so careful medical oversight is important. 15063 15085 15050 15091

The Emerging Field of Psychedelic Psychotherapy

Gregory Barber, Scott T. Aaronson
Current Psychiatry Reports Summary & key facts 2022 48 citations

This review looks at recent research where drugs like MDMA and psilocybin are given inside carefully run therapy programs. People get hours of preparation, one or more drug sessions, and several follow-up therapy sessions to help make sense of the experience. Trials so far show big improvements for some people…

Chemical synthesis and alkaloids Diverse academic research themes Psychedelics and Drug Studies Ayahuasca Ibogaine

Effects of Psychedelics in Older Adults: A Prospective Cohort Study

Hannes Kettner, Leor Roseman, Adam Gazzaley, Robin Carhart‐Harris, Lorenzo Pasquini

Researchers followed 62 older adults (age 60 and up) and 62 younger adults who planned to take part in guided psychedelic group sessions. People in both age groups reported better well-being in the weeks after the sessions, but older adults experienced weaker immediate drug effects during the sessions. For older…

Biochemical Analysis and Sensing Techniques Chemical synthesis and alkaloids Psychedelics and Drug Studies Ayahuasca LSD

Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders

Nataliya S. Vorobyeva, Alena A. Kozlova
Frontiers in Pharmacology Summary & key facts 2022 14 citations

This paper reviews research on three naturally occurring psychedelics: psilocybin, ibogaine, and N,N-dimethyltryptamine (the active part of the brew ayahuasca). It explains that these drugs work on the brain's serotonin system and summarizes growing studies that suggest they might help with problems like post-traumatic stress disorder, major depression, anxiety, and…

Chemical synthesis and alkaloids Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies Ayahuasca Ibogaine
Summaries and links are for general information and education only. They are not a substitute for reading the original publication or for professional medical, legal, or other advice. Always refer to the linked source for the full study.